The Biostatistics Core of the Cancer Center was established in 1994 with the goal of assuring appropriateDiostatistical support to cancer-related research at UCSF. The Core provides partial support to ninestatisticians, five of which are UCSF faculty, who together cover the extensive breadth of expertise requiredfor Cancer Center projects. The Core has the expertise to support in vitro and animal research, clinicalresearch and population research, including studies of genetic and environmental disease etiology andprevention, and studies of disease interventions with either curative or palliative intent. The Core providesservices on a charge-back basis, and it participates in the design of studies prior to grant submission withcore statisticians subsequently being supported as coinvestigators if funding is obtained. The statisticiansalso serve as coinvestigators or P.l.s on projects that they develop. One of the major functions of the Core isto assure that novel analytical approaches developed in one project are rapidly available to all CancerCenter investigators.The major functions of the Biostatistics Core include the following: (1) the coordination and management ofthe statistical activities in the Cancer Center; (2) the provision of biostatistical expertise and support foranalysis of laboratory data; (3) the guidance of statistical aspects of study design and conduct as they relateto the ability to interpret study results; (4) the performance of statistical analysis and reporting of studyresults using contemporary statistical methods; (5) the provision of support for protocol review and datasafety monitoring; and (6) the provision of training and education in biostatistics to Cancer Centerinvestigators, staff, oncology residents, and fellows. Core personnel also perform statistical research withinthe context of Cancer Center projects or projects for which they have obtained independent funding.
| Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131: |
| Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228 |
| Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408 |
| Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279 |
| Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380 |
| Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485 |
| An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575 |
| Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3: |
| Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607 |
| An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794 |
Showing the most recent 10 out of 192 publications
